

**NAMSDL**



**National Alliance for Model State Drug Laws**

**TABLE OF CATHINONES AND  
CATHINONE DERIVATIVES  
BILLS, STATUTES & REGULATIONS**

© 2011 Research is current as of March 4, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or [hgray@namsdl.org](mailto:hgray@namsdl.org) with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

The following table illustrates what the states are doing with regard to scheduling cathinones and cathinone derivatives and, where indicated, which states have already scheduled the substances by statute (S) or regulation (R).

	<u>cathinone</u> <sup>1</sup>	<u>methcathinone</u> <sup>2</sup>	<u>mephedrone</u> <sup>3</sup>	<u>methedrone</u> <sup>4</sup>	<u>Flephedrone</u> <sup>5</sup>	<u>3-FMC</u> <sup>6</sup>	<u>methylone</u> <sup>7</sup>	<u>MDPV</u> <sup>8</sup>
Alabama	X(R)	X(R)	X		X	X	X	X
Alaska		X(S)						
Arizona	X(S)	X(S)						
Arkansas	X(R)	X(R)	X	X	X	X	X	X
California	X(S)							
Colorado	X(S)	X(S)						
Connecticut	X(R)	X(R)						
Delaware	X(S)	X(S)						

<sup>1</sup> 2-amino-1-phenyl propanone

<sup>2</sup> 2-methylamino-1-phenylpropan-1-one

<sup>3</sup> 4-methylmethcathinone; 4-MMC; 4-methylephedrone; (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one

<sup>4</sup> Bk-PMMA; para-methoxymethcathinone; 4-methoxymethcathinone; PMMC; methoxyphedrine; (RS)-1-(4-methoxyphenyl)-2-(methylamino)propan-1-one

<sup>5</sup> 4-fluoromethcathinone

<sup>6</sup> 3-fluoromethcathinone

<sup>7</sup> 3,4-methylenedioxy-N-methylcathinone; bk-MDMA; MDMC

<sup>8</sup> Methylenedioxypropylone; MDPK; 3,4-methylenedioxypropylone

© 2011 Research is current as of March 4, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

District of Columbia	X(S)							
Florida <sup>9</sup>	X(S)	X(S)	X(R)		X(R)	X(R)	X(R)	X(R)
Georgia	X(S)	X(S)	X	X	X		X	X
Hawaii	X(S)	X(S)	X					X
Idaho	X(S)	X(S)						
Illinois <sup>10</sup>	X(S)	X(S)						X
Indiana	X(S)	X(S)						
Iowa	X(S)	X(S)	X <sup>11</sup>					X
Kansas <sup>12</sup>	X(S)	X(S)						
Kentucky	X(R)	X(S)	X				X	X

<sup>9</sup> Florida scheduled mephedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone and MDPV by rule on an emergency basis on January 26, 2011. 2ER11-1. Florida is proposing to schedule all substances except methedrone, but has proposed to schedule 3-methoxymethcathinone which may be methedrone.

<sup>10</sup> Illinois is proposing to add the ACMD generic language.

<sup>11</sup> Iowa is proposing to schedule (RS)-2-methylamino-1-(4-methylphenyl)propan-1-one, a/k/a 4-MMC, as "mephedrine."

<sup>12</sup> Kansas is proposing to add a version of the ACMD generic language.

Louisiana <sup>13</sup>	X(S)	X(S)	X(R)	X(R)	X(R)	X(R)	X(R)	X(R)
Maine								
Maryland			X	X	X	X	X	X
Massachusetts								
Michigan	X(S)	X(S)	X <sup>14</sup>					
Minnesota	X(S)	X(S)						
Mississippi	X(S)	X(S)	X					X
Missouri	X(S)	X(S)	X <sup>15</sup>					X
Montana	X(S)	X(S)						
Nebraska	X(S)	X(S)						
Nevada	X(R)	X(R)						

<sup>13</sup> Louisiana scheduled mephedrone, methedrone, 4-fluoromethcathinone, 3-fluoromethcathinone, methylone, and MDPV by regulation on an emergency basis on January 20, 2011. 2011 Reg. Text 247982.

<sup>14</sup> Michigan schedules 4-methylmethcathinone as “mephradone” under M.C.L.A. §333.7212.

<sup>15</sup> Missouri is proposing to schedule 4-methylmethcathinone as “mephradone.”

New Hampshire <sup>16</sup>	X(R)	X(R)						
New Jersey								
New Mexico <sup>17</sup>	X(R)	X(R)	X		X	X	X	X
New York <sup>18</sup>	X(S)	X(S)	X	X	X	X	X	X
North Carolina	X(S)	X(S)	X					X
North Dakota	X(S)	X(S)	X(R) <sup>19</sup>					X(R)
Ohio	X(S)	X(S)	X	X	X	X	X	X
Oklahoma		X(S)	X	X	X	X	X	X
Oregon	X(R)	X(R)						
Pennsylvania	X(R)	X(R)	X	X	X	X	X	X

<sup>16</sup> New Hampshire references the federal code, 21 USC 801, et seq., for its list of scheduled substances.

<sup>17</sup> New Mexico is proposing to schedule 3-methoxymethcathinone which may be methedrone.

<sup>18</sup> New York is proposing to add the ACMD generic language.

<sup>19</sup> North Dakota also has a proposed bill, 2011 ND S.B. 2119, that would schedule mephedrone by statute.

© 2011 Research is current as of March 4, 2011. In order to ensure that the information contained herein is as current as possible, research is conducted using both nationwide legal database software and individual state legislative websites. Please contact Heather Gray at (703) 836-6100, ext. 114 or hgray@namsdl.org with any additional updates or information that may be relevant to this document. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: THE NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS, 215 Lincoln Ave. Suite 201, Santa Fe, NM 87501.

Rhode Island			X	X <sup>20</sup>	X <sup>21</sup>	X	X	X
South Carolina								
South Dakota	X(S)	X(S)						
Tennessee <sup>22</sup>	X(R)	X(R) (S)	X	X	X	X	X	X
Texas <sup>23</sup>	X(S)	X(S)	X	X	X	X	X	X
Utah	X(S)	X(S)	X	X	X	X	X	X
Vermont		X(R)						
Virginia	X(S)	X(S)	X					X
Washington	X(S)	X(S)						
West Virginia	X(S)	X(S)	X <sup>24</sup>					X

<sup>20</sup> Rhode Island is proposing to schedule “methoxymethcathinone” generally.

<sup>21</sup> Rhode Island is proposing to schedule “fluoromethcathinone” generally.

<sup>22</sup> Tennessee schedules methcathinone by both statute and regulation. Tenn. Code Ann. §39-17-406 classifies methcathinone and *Catha edulis* as Schedule I drugs when cathinone is present, and *Catha edulis* as a Schedule IV drug (TCA §39-17-412) when cathinone is absent but cathine is present. TN ADC 0940-06-01-.01 schedules both cathinone and methcathinone as Schedule I substances.

<sup>23</sup> Texas is also proposing to add the generic ACMD language.

<sup>24</sup> West Virginia seeks to add mephedrone to its list of alternate names for methcathinone.

Wisconsin	X(S)	X(S)						
Wyoming	X(S)	X(S)	X	X	X	X	X	X

(S) = Substance is scheduled by statute

(R) = Substance is scheduled or proposed to be scheduled by regulation